FDA Corrects Draft Guidance on Listed Drugs and ANDA Approval Process

Summary

The FDA is correcting a notice regarding a draft guidance on listed drugs, 30-month stays, and approval of ANDAs and 505(b)(2) applications, which was published with an incorrect docket number, following amendments to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.